Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms × Dasatinib × Clear all

Phase

Phase 2 7 Phase 1 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Chronic-Phase 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Leukemia 3 Burkitt Lymphoma 2 Prostatic Neoplasms 1 Philadelphia Chromosome 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1 Bronchiolitis Obliterans Syndrome 1

Interventions

Docetaxel 43 Prednisone 42 Radiotherapy 41 Goserelin 39 Leuprolide 37 bicalutamide 35 enzalutamide 25 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 24 Androgen Antagonists 22 Flutamide 19 Triptorelin Pamoate 17 apalutamide 15 Zoledronic Acid 12 Gonadotropin-Releasing Hormone 12 Abiraterone Acetate 12 gallium 68 PSMA-11 11 abiraterone 11 Radiation 11 Magnetic Resonance Spectroscopy 11 Prednisolone 9 Estramustine 8 Dexamethasone 8 Specimen Handling 7 Chemotherapy, Adjuvant 7 Buserelin 7 orteronel 6 luprolide acetate gel depot 6 darolutamide 6 cabazitaxel 6 Standard of Care 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00744497 2016-10-17

READY

Bristol-Myers Squibb

Phase 3 Completed

1,930 enrolled 23 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡